牛牛AI助理已提取核心訊息
On February 2, 2024, ProSomnus, Inc., a Delaware corporation, filed a post-effective amendment to its Form S-1 on Form S-3 with the Securities and Exchange Commission (SEC). This filing is intended to convert the previously filed Registration Statement on Form S-1 into a registration statement on Form S-3. The original Registration Statement was declared effective by the SEC on December 14, 2023. The amendment does not register any additional securities and states that all applicable registration and filing fees were paid during the original filing. The prospectus included in the amendment details a secondary offering of up to 44,913,872 shares of common stock, which may be issued upon the exercise of warrants, the conversion of Series A Preferred Stock, as dividends on the Series A Preferred Stock, and upon conversion of convertible notes. ProSomnus, Inc. is a company specializing in the manufacture of precision, mass-customized oral appliance therapy devices to treat obstructive sleep apnea. The company's common stock is listed on the Nasdaq Global Market under the symbol 'OSA'.
On February 2, 2024, ProSomnus, Inc., a Delaware corporation, filed a post-effective amendment to its Form S-1 on Form S-3 with the Securities and Exchange Commission (SEC). This filing is intended to convert the previously filed Registration Statement on Form S-1 into a registration statement on Form S-3. The original Registration Statement was declared effective by the SEC on December 14, 2023. The amendment does not register any additional securities and states that all applicable registration and filing fees were paid during the original filing. The prospectus included in the amendment details a secondary offering of up to 44,913,872 shares of common stock, which may be issued upon the exercise of warrants, the conversion of Series A Preferred Stock, as dividends on the Series A Preferred Stock, and upon conversion of convertible notes. ProSomnus, Inc. is a company specializing in the manufacture of precision, mass-customized oral appliance therapy devices to treat obstructive sleep apnea. The company's common stock is listed on the Nasdaq Global Market under the symbol 'OSA'.
2024年2月2日，特拉華州的一家公司ProSomnus, Inc. 向美國證券交易委員會（SEC）提交了S-3表格S-1的生效後修正案。本文件旨在將先前在表格S-1上提交的註冊聲明轉換爲表格S-3上的註冊聲明。美國證券交易委員會於2023年12月14日宣佈最初的註冊聲明生效。該修正案沒有登記任何其他證券，並規定所有適用的註冊和申請費都是在最初的申報期間支付的。修正案中包含的招股說明書詳細說明了最多44,913,872股普通股的二次發行，可以在行使認股權證、將A系列優先股轉換爲A系列優先股的股息以及轉換可轉換票據時發行。Prosomnus, Inc. 是一家專門生產用於治療阻塞性睡眠呼吸暫停的精密、大規模定製口服器械治療設備的公司。該公司的普通股在納斯達克全球市場上市，股票代碼爲 “OSA”。
2024年2月2日，特拉華州的一家公司ProSomnus, Inc. 向美國證券交易委員會（SEC）提交了S-3表格S-1的生效後修正案。本文件旨在將先前在表格S-1上提交的註冊聲明轉換爲表格S-3上的註冊聲明。美國證券交易委員會於2023年12月14日宣佈最初的註冊聲明生效。該修正案沒有登記任何其他證券，並規定所有適用的註冊和申請費都是在最初的申報期間支付的。修正案中包含的招股說明書詳細說明了最多44,913,872股普通股的二次發行，可以在行使認股權證、將A系列優先股轉換爲A系列優先股的股息以及轉換可轉換票據時發行。Prosomnus, Inc. 是一家專門生產用於治療阻塞性睡眠呼吸暫停的精密、大規模定製口服器械治療設備的公司。該公司的普通股在納斯達克全球市場上市，股票代碼爲 “OSA”。
有用
沒用